

Patient Reported Satisfaction and Improvement of Neck Appearance With VYC-12L: Results From a Multicenter, Evaluator-Blinded, Randomized, Controlled Study

Sue Ellen Cox,¹ Melanie D. Palm,² Cheryl Burgess,³ Rebecca Kazin,⁴ Tam Nguyen,⁵ Julia K. Garcia,⁶ Smita Chawla⁵

¹Aesthetic Solutions, Chapel Hill, NC, USA; ²Art of Skin MD, Solana Beach, CA, USA; ³Center for Dermatology and Dermatologic Surgery, Washington DC, USA; ⁴ICON Dermatology and Aesthetics, North Bethesda, MD, USA; ⁵Allergan Aesthetics, an AbbVie company, Irvine, CA, USA; ⁶AbbVie Inc., Irvine, CA, USA

OBJECTIVE

To evaluate patient-reported outcomes following VYC-12L treatment for reducing neck lines to improve neck appearance

CONCLUSIONS



Treatment with VYC-12L led to high participant satisfaction and decreased negative psychosocial impact due to neck appearance through 6 months in a majority of participants across multiple validated patient-reported outcome measures



Repeat treatment with VYC-12L maintained or improved upon the effects of initial treatment, with no treatment-related treatment-emergent adverse events reported



Treatment with VYC-12L was well-tolerated, with a safety profile consistent with other HA-based injectables, including VYC-12L for cheek smoothness¹

For additional information or to obtain a PDF of this poster

Scan QR code or use the following link to download an electronic version of this presentation and other Allergan Aesthetics and AbbVie 2026 SCALE scientific presentations:

https://abbvie1_outsystemsenterprise.com/CongressPublications/CongressHome?CongressId=53c07a5a-4b77-436e-a3d5-30a78ac1d5c7

QR code expiration: April 18, 2027

To submit a medical question, please visit www.abbviemedinfo.com



Allergan Aesthetics, an AbbVie company, and the authors thank the participants, study sites, and investigators who participated in this clinical trial. Allergan Aesthetics, an AbbVie company, funded this trial and participated in the trial design, research, analysis, data collection, interpretation of data, and the review and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Graham Kaplan, PhD, of AbbVie Inc. and funded by AbbVie Inc.

Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors: S. E. Cox and C. Burgess are principal investigators for Allergan Aesthetics, an AbbVie company; M. Palm is a consultant and principal investigator for Allergan Aesthetics, an AbbVie company; R. Kazin is a principal investigator for Allergan Aesthetics, an AbbVie company, and a principal investigator and speaker for Galderma. S. Chawla, J. Garcia, and T. Nguyen are employees of AbbVie Inc. and may own company stock.

References

- Alexiades et al. *Dermatol Surg*. 2023;1(49):682-688.
- Kaufman et al. A multicenter, evaluator-blinded, randomized, controlled study of the effectiveness and safety of VYC-12L for treating neck lines and improving neck appearance. Presented at: American Society for Dermatologic Surgery (ASDS); November 13-15, 2025; Chicago, IL. Video poster.

INTRODUCTION

VYC-12L (Allergan Aesthetics, an AbbVie company, Irvine, CA) is a 12-mg/mL hyaluronic acid injectable gel with 0.3% w/w lidocaine

VYC-12L is approved in the US for intradermal injection to the cheeks to improve skin smoothness in adults over the age of 21¹


VYC-12L is an effective and well tolerated treatment for reducing neck lines and improving neck appearance²

Here, we report patient-reported outcome (PRO) measures from a study of VYC-12L treatment for reducing neck lines to improve neck appearance

METHODS

Study Design

Participants: Adults (>21 years) rated *Moderate* or *Severe* on the Allergan Transverse Necklines Scale (ATNLS) at baseline by an evaluating investigator



Treatment Administration

- Treatment Administration:** 32G ½" needle only or with optional 25G 1½" cannula
- Plane of injection:** Intradermal or subdermal
- Volume:** Up to 3 mL for initial treatment, 2 mL for touch-up treatment, and 3 mL for repeat treatment (if administered)

Safety


- Safety Assessments**
- Injection site responses (ISRs) – type, severity and duration
 - Adverse events (AEs) – type, severity, and duration

RESULTS


Baseline Demographics and Characteristics

	Control (n = 54)	VYC-12L (n = 105)
Mean age, years	47.1	50.3
Sex, (%)		
Female	53 (98.1)	101 (96.2)
Male	1 (1.9)	4 (3.8)
Race		
American Indian or Alaska Native	3 (5.6)	4 (3.8)
Asian	3 (5.6)	8 (7.6)
Black or African American	6 (11.1)	5 (4.8)
Multiple Races	1 (1.9)	3 (2.9)
Native Hawaiian or Other Pacific Islander	0 (0.0)	2 (1.9)
White	41 (75.9)	83 (79.0)
Fitzpatrick skin type, n (%)		
Type I/II	16 (29.6)	26 (24.8)
Type III/IV	32 (59.3)	67 (63.8)
Type V/VI	6 (11.1)	12 (11.4)
Baseline ATNLS score, n (%)		
Grade 2 – Moderate	21 (38.9)	36 (34.3)
Grade 3 – Severe	33 (61.1)	69 (65.7)


Neck Appearance: Most Participants Reported Improved Neck Appearance at Month 1 That Lasted Through Month 6, and Repeat Treatment Led to Further Improvements




Satisfaction With Neck Appearance: Participants Reported Increased Satisfaction With the Appearance of Their Neck at Month 1 That Lasted Through Month 6, and Repeat Treatment Further Enhanced Satisfaction



Psychosocial Impact: Participants Reported Decreased Negative Psychosocial Impact Due to Neck Appearance at Month 1 That Lasted Through Month 6, and Repeat Treatment Led to Further Improvements



Satisfaction With Treatment: A Majority of the Participants Were Satisfied With Treatment at Month 1 Remained Satisfied Through Month 6, and Repeat Treatment Further Increased Satisfaction



Error bars indicate the 95% CI. ANTOS-Satisfaction, Allergan Neck Treatment Outcome Scale – Satisfaction With Neck; ANSS-Psychosocial, Allergan Neck Satisfaction Scale Psychosocial Impact; ANSS-Satisfaction, Allergan Neck Satisfaction Scale for Neck Appearance; GAIS, Global Aesthetic Improvement Scale; M1, month 1; M2, month 2; M4, month 4; M6, month 6.


Patient-Reported Outcome Measures and Associated Endpoints

All PRO measures were developed in accordance with FDA guidelines and validated*

Global Aesthetic Improvement Scale for Neck Appearance (GAIS)	<ul style="list-style-type: none"> A single item on a 5-point scale ranging from <i>Much Worse</i> to <i>Much Improved</i> Participants (%) who showed improvement in their neck appearance at month 1 (<i>Improved</i> or <i>Much Improved</i>)
Allergan Neck Satisfaction Scale – Appearance of the Neck (ANSS–Appearance)	<ul style="list-style-type: none"> A 15-point assessment of satisfaction with neck appearance (0 = worst, 15 = best) Change from baseline in the mean overall score for neck appearance at month 1
Allergan Neck Satisfaction Scale – Psychosocial Impact (ANSS–Psychosocial)	<ul style="list-style-type: none"> An 18-point assessment of negative psychosocial impact due to neck appearance (0 = best, 18 = worst) Change from baseline in the mean overall score for psychosocial impact at month 1
Allergan Neck Treatment Outcome Scale – Satisfaction with Treatment (ANTOS–Satisfaction)	<ul style="list-style-type: none"> A single item on a 5-point scale ranging from <i>Very Dissatisfied</i> to <i>Very Satisfied</i> Participants (%) who reported being satisfied (<i>Mostly Satisfied</i> or <i>Very Satisfied</i>) with treatment at month 1

*GAIS is a global measure that does not require validation

Participant Photographs and 3D Images Reveal Reduced Neck Lines and Improved Neck Appearance at Month 1



Top panels: Participant is female, Black, aged 48 years, rated Severe on ATNLS at Baseline. Participant received initial (3.0 mL) and touch-up (2.0 mL) treatments. ATNLS at month 1: Minimal
Bottom panels: Participant is female, White, aged 56 years, rated Moderate on ATNLS at Baseline. Participant received initial (1.5 mL) and touch-up (0.6 mL) treatments. ATNLS at month 1: Minimal
PRIMOS, Phaseshift rapid in-vivo measurement of skin;

Safety

Treatment-Related TEAEs	VYC-12L (N = 105)	VYC-12L Post-Control (n = 43)	Repeat Treatment (n = 46)
Type, n (%)			
Injection site mass	5 (4.8)	0 (0.0)	0 (0.0)
Injection site papule	1 (0.7)	0 (0.0)	0 (0.0)
Severity, n (%)			
Mild	4 (3.8)	0 (0.0)	0 (0.0)
Moderate	1 (1.0)	0 (0.0)	0 (0.0)
Severe			

ATNLS, Allergan Transverse Necklines Scale; HA, hyaluronic acid; TEAEs, treatment-emergent adverse events

All treatment-related TEAEs resolved without sequelae